Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Brazzelli M, Cruickshank M, Tassie E, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Oct. (Health Technology Assessment, No. 19.90.)
Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation.
Show detailsTABLE 41
Domain (type of bias assessed) | Badalamente 200264 | Badalamente 200765 | Hurst 200955 | Gilpin 201056 |
---|---|---|---|---|
Sequence generation (selection bias) | ? | ? | ✓ | ✓ |
Allocation concealment (selection bias) | ? | ? | ✓ | ✓ |
Blinding of participants (performance bias) | ✓ | ✓ | ✓ | ✓ |
Blinding of health-care providers (performance bias) | ✓ | ✓ | ✓ | ? |
Blinding of outcome assessment (detection bias) | ? | ? | ? | ? |
Groups treated identically (performance bias) | ✓ | ✓ | ✓ | ✓ |
Incomplete outcome data (attrition bias) | ? | ✓ | ✓ | ✓ |
Intention to treat (attrition bias) | ✓ | ✓ | ✓ | ✓ |
Selective reporting (reporting bias) | ✓ | ✗ | ✓ | ✓ |
Other bias | ✗ | ✗ | ✗ | ✗ |
✓, low risk of bias; ✗, high risk of bias; ?, unclear risk of bias.
- Risk-of-bias assessment for individual collagenase randomised controlled trials ...Risk-of-bias assessment for individual collagenase randomised controlled trials - Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...